Blockade of HIF-1α and STAT3 by hyaluronate-conjugated TAT-chitosan-SPION nanoparticles loaded with siRNA molecules prevents tumor growth

Budi, Hendrik Setia; Izadi, Sepideh; Timoshin, Anton; Asl, Sima Heydarzadeh; Beyzai, Behzad; Ghaderpour, Amir; Alian, Fatemeh; Eshaghi, Farzaneh Sadat; Mousavi, Seyedeh Mahboubeh; Rafiee, Behnam; Nikkhoo, Afshin; Ahmadi, Armin; Hassannia, Hadi; Ahmadi, Majid; Sojoodi, Mozhdeh; Jadidi‐Niaragh, Farhad

doi:10.1016/j.nano.2021.102373

Cited by 22 publications

(10 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, CHA-Np was utilized to entrap super magnetic iron oxide nanoparticles and TAT peptides for siRNA delivery against STAT3 and HIF-1 α. The nanoparticles (118 nm) inhibited proliferation, migration, and increased apoptosis in the CT26 cell line according to the findings of this study [73]. Other nanoparticles were used to deliver anti-IL-6 and BV6 utilizing chitosan-hyaluronic acid-PEG.…”

Section: Colon Cancersupporting

confidence: 61%

“…The efficiency of CHA-Np has been demonstrated in many cancer cell lines (in vitro), with an increase in apoptosis-inducing proteins, decreased proliferation, mutation, and angiogenesis, as well as the inhibition of cell viability [63,73]. Whereas in vivo, which was tested mostly on mice that had been inoculated with cancer cells, these nanoparticles were able to reduce tumor volume and size, the conjugated hyaluronic acid was able to deliver nanoparticles to cancer sites more than in other normal tissues [76,79].…”

Section: Author Perspectivementioning

confidence: 99%

See 1 more Smart Citation

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

Cancer is the most common cause of death worldwide; therefore, there is a need to discover novel treatment modalities to combat it. One of the cancer treatments is nanoparticle technology. Currently, nanoparticles have been modified to have desirable pharmacological effects by using chemical ligands that bind with their specific receptors on the surface of malignant cells. Chemical grafting of chitosan nanoparticles with hyaluronic acid as a targeted ligand can become an attractive alternative for active targeting. Hence, these nanoparticles can control drug release with pH- responsive stimuli, and high selectivity of hyaluronic acid to CD44 receptors makes these nanoparticles accumulate more inside cells that overexpress these receptors (cancer cells). In this context, we discuss the benefits and recent findings of developing and utilizing chitosan–hyaluronic acid nanoparticles against distinct forms of cancer malignancy. From here we know that chitosan–hyaluronic acid nanoparticles (CHA-Np) can produce a nanoparticle system with good characteristics, effectiveness, and a good active targeting on various types of cancer cells. Therefore, this system is a good candidate for targeted drug delivery for cancer therapy, anticipating that CHA-Np could be further developed for various cancer therapy applications.

show abstract

Section: Colon Cancersupporting

confidence: 61%

Section: Author Perspectivementioning

confidence: 99%

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A number of different peptide‐conjugated NPs were used to deliver siRNA such as chitosan, [107] liposomes, [108] magnetic NPs, [109] PEG‐PLA NPs, [110] lipid NPs, [111] superparamagnetic iron oxide NPs, [112] and gold NPs [113] . In addition to siRNA, peptide‐conjugated nanoparticles were used to deliver CRISPR‐Cas9 plasmid, [114] plasmid DNA, [115] anti‐microRNA,, [116] and circular DNA [117] .…”

Section: Peptide‐conjugated Nanoparticles For Drug Deliverymentioning

confidence: 99%

Peptide‐conjugated Nanoparticle Platforms for Targeted Delivery, Imaging, and Biosensing Applications

Ilieş,

Yildiz,

Abbas

2024

ChemBioChem

View full text Add to dashboard Cite

Peptides have become an indispensable tool in engineering of multifunctional nanostructure platforms for biomedical applications such as targeted drug and gene delivery, imaging and biosensing. They can be covalently incorporated into a variety of nanoparticles (NPs) including polymers, metallic nanoparticles, and others. Using different bioconjugation techniques, multifunctional peptide‐modified NPs can be formulated to produce therapeutical and diagnostic platforms offering high specificity, lower toxicity, biocompatibility, and stimuli responsive behavior. Targeting peptides can direct the nanoparticles into specific tissues for targeted drug and gene delivery and imaging applications due to their specificity towards certain receptors. Furthermore, due to their stimuli‐responsive features, they can offer controlled release of therapeutics into desired sites of disease. In addition, peptide‐based biosensors and imaging agents can provide non‐invasive detection and monitoring of diseases including cancer, infectious diseases, and neurological disorders. In this review, we covered the design and formulation of recent peptide‐based NP platforms, as well as their utilization in in vitro and in vivo applications such as targeted drug and gene delivery, targeting, sensing, and imaging applications. In the end, we provided the future outlook to design new peptide conjugated nanomaterials for biomedical applications.

show abstract

“…Researchers used SPION-NPs coated with thiolated chitosan (ChT) and trimethyl chitosan (TMC) and functionalized with hyaluronate (H) and TAT peptide for delivery of siRNA molecules against STAT3 and HIF-1α to cancer cells both in vivo and in vitro . The results indicated that tumor cell transfection with siRNA-encapsulated NPs robustly inhibited proliferation and migration and induced apoptosis in breast cancer cells ( Budi et al, 2021 ). Similarly, researchers utilized superparamagnetic iron oxide-based NPs (SPIONs) combined with chitosan lactate (CL) and folic acid (FA) nanoparticles (NPs) loaded with TIGIT-siRNA and HIF-1α-siRNA for suppressing TIGIT and HIF-1α in tumor cells in another study.…”

Section: Therapeutic Strategies Targeting Hif-1α In Bcmentioning

confidence: 99%

Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

Luo

Jiang²,

Zheng

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Hypoxia-inducible factors (HIFs), central regulators for cells to adapt to low cellular oxygen levels, are often overexpressed and activated in breast cancer. HIFs modulate the primary transcriptional response of downstream pathways and target genes in response to hypoxia, including glycolysis, angiogenesis and metastasis. They can promote the development of breast cancer and are associated with poor prognosis of breast cancer patients by regulating cancer processes closely related to tumor invasion, metastasis and drug resistance. Thus, specific targeting of HIFs may improve the efficiency of cancer therapy. In this review, we summarize the advances in HIF-related molecular mechanisms and clinical and preclinical studies of drugs targeting HIFs in breast cancer. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for HIF targeting are increasingly being developed. Therefore, we highlight the HIF related DDS, including liposomes, polymers, metal-based or carbon-based nanoparticles.

show abstract

Blockade of HIF-1α and STAT3 by hyaluronate-conjugated TAT-chitosan-SPION nanoparticles loaded with siRNA molecules prevents tumor growth

Cited by 22 publications

References 67 publications

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

Chitosan–Hyaluronic Acid Nanoparticles for Active Targeting in Cancer Therapy

Peptide‐conjugated Nanoparticle Platforms for Targeted Delivery, Imaging, and Biosensing Applications

Targeting hypoxia-inducible factors for breast cancer therapy: A narrative review

Contact Info

Product

Resources

About